ReviewVaccines2022
Cell Lines for the Development of African Swine Fever Virus Vaccine Candidates: An Update.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- A dual-gene-deleted ASFV Lv17/WB/Rie1-ΔCD candidate administered orally to wild boar confers DIVA-compatible protection against virulent challenge.The veterinary quarterly · 2026Article
- Cell Culture Adaptation of Porcine Group A Rotavirus: Advances and Challenges for Vaccine Development.Viruses · 2026Review
- RPSA enhances African swine fever virus entry via caveola-mediated endocytic pathway.Journal of virology · 2026Article
- Evaluation of Cryopreserved Primary Swine Macrophages as a Substrate for African Swine Fever Virus Replication.Methods and protocols · 2026Article
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
- Article
- Temporally integrated multiomics analysis elucidates intricate regulatory mechanisms of ASFV in a wild boar lung-derived clonal cell line.Veterinary research · 2025Article
- Highly suitable LFBK cells for African swine fever virus replication and type I interferon-induced immune studies.Veterinary research · 2025Article
- A Practical Framework for ASFV Disinfectant Evaluation: Differentiating Cytopathic Effects from Cytotoxicity via Integrated Analytical Methods.Pathogens (Basel, Switzerland) · 2025Article
- Establishment of a highly sensitive porcine alveolar macrophage cell line for African swine fever virus.In vitro cellular & developmental biology. Animal · 2025Article
- Genetic and biological characterization of African swine fever virus clones selected at the early stages of adaptation in Vero cells.Archives of virology · 2025Article
- Synergy between pluripotent stem cell-derived macrophages and self-renewing macrophages: Envisioning a promising avenue for the modelling and cell therapy of infectious diseases.Cell proliferation · 2025Review
- The Potential of Disabled Infectious Single Cycle (DISC) Virus Platforms for Next Generation African Swine Fever Vaccine Development.Transboundary and emerging diseases · 2025Review
- Navigating the threat of African swine fever: a comprehensive review.Tropical animal health and production · 2024Review
- Challenges in the Application of African Swine Fever Vaccines in Asia.Animals : an open access journal from MDPI · 2024Article
- Article
- Testing multiplexed anti-ASFV CRISPR-Cas9 in reducing African swine fever virus.Microbiology spectrum · 2024Article
- A porcine kidney-derived clonal cell line with clear genetic annotation is highly susceptible to African swine fever virus.Veterinary research · 2024Article
- CA-CAS-01-A: A Permissive Cell Line for Isolation and Live Attenuated Vaccine Development Against African Swine Fever Virus.Journal of microbiology (Seoul, Korea) · 2024Article
- Differential infection behavior of African swine fever virus (ASFV) genotype I and II in the upper respiratory tract.Veterinary research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
African swine fever virus (ASFV) is the etiological agent of a highly lethal disease in both domestic and wild pigs. The virus has rapidly spread worldwide and has no available licensed vaccine. An obstacle to the construction of a safe and efficient vaccine is the lack of a suitable cell line for ASFV isolation and propagation. Macrophages are the main targets for ASFV, and they have been widely used to study virus-host interactions; nevertheless, obtaining these cells is time-consuming and expensive, and they are not ethically suitable for the production of large-scale vaccines. To overcome these issues, different virulent field isolates have been adapted on monkey or human continuous cells lines; however, several culture passages often lead to significant genetic modifications and the loss of immunogenicity of the adapted strain. Thus, several groups have attempted to establish a porcine cell line able to sustain ASFV growth. Preliminary data suggested that some porcine continuous cell lines might be an alternative to primary macrophages for ASFV research and for large-scale vaccine production, although further studies are still needed. In this review, we summarize the research to investigate the most suitable cell line for ASFV isolation and propagation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.